ArticleCureus2026

NeoProspect HER2-low: Response and Prognosis After Neoadjuvant Treatment in Patients with HER2-low Breast Cancer.

Laura Pratas Guerra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.